News
Compounded weight loss drugs have been mostly off the market for about a month, but the weight loss drug industry remains as ...
Below are a few more promising studies of weight-loss drugs. Combining bimagrumab, an investigational human monoclonal antibody that binds to and inhibits activin receptor type-2B, with semaglutide ...
Novo Nordisk A/S scrapped a partnership with Hims & Hers Health Inc. after less than two months, saying the US company is ...
Novo Nordisk shares tumble 5.6% after ending Hims & Hers partnership and releasing disappointing CagriSema obesity drug trial ...
GLP-1 drugs like Ozempic and Zepbound are great at promoting weight loss, but they also cause folks to lose muscle along with ...
Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy in India, three months after Eli ...
Novo Nordisk ends Wegovy deal with Hims over legal issues, sending the stock tumbling. What happens next? Here's a look.
Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for patients who have a prescription for the medication but no insurance coverage ...
Hims & Hers Health Inc.'s stock booked record losses Monday after pharmaceutical giant Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ending a collaboration with the telehealth ...
U.S. pharma companies should pay rather more of their corporate income tax in the U.S.—and start producing more of their best drugs in the U.S. as well.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results